mTOR inhibition, a potential novel approach for bronchial carcinoids

Endocrine-Related Cancer

Volumn 18, Issue 3, 2011, Pages

  Dong, Mei ^a   Yao, James C ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; CHROMOGRANIN A; EVEROLIMUS; OCTREOTIDE; PASIREOTIDE; PLACEBO; SOMATOMEDIN; VASCULOTROPIN; VASCULOTROPIN INHIBITOR;

BRONCHUS CARCINOID; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CELL PROLIFERATION; CYTOTOXICITY; DRUG EFFICACY; DRUG SAFETY; HETEROZYGOSITY LOSS; HUMAN; INTENTION TO TREAT ANALYSIS; NEUROENDOCRINE TUMOR; NOTE; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; SIGNAL TRANSDUCTION; SURVIVAL RATE; TUMOR CELL LINE; TUMOR GROWTH;

ANTINEOPLASTIC AGENTS; BRONCHIAL NEOPLASMS; CARCINOID TUMOR; DISEASE-FREE SURVIVAL; HUMANS; MOLECULAR TARGETED THERAPY; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 79960094413     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-10-0290     Document Type: Note

References (23)

1. Asamura H, Kameya T, Matsuno Y, Noguchi M, Tada H, Ishikawa Y, Yokose T, Jiang SX, Inoue T, Nakagawa K et al. 2006 Neuroendocrine neoplasms of the lung: a prognostic spectrum. Journal of Clinical Oncology 24 70-76. (doi:10.1200/JCO.2005.04.1202)
2. Cardillo G, Sera F, Di Martino M, Graziano P, Giunti R, Carbone L, Facciolo F & Martelli M 2004 Bronchial carcinoid tumors: nodal status and long-term survival after resection. Annals of Thoracic Surgery 77 1781-1785. (doi:10.1016/j.athoracsur.2003.10.089)
3. Debelenko LV, Brambilla E, Agarwal SK, Swalwell JI, Kester MB, Lubensky IA, Zhuang Z, Guru SC, Manickam P, Olufemi SE et al. 1997 Identification of MEN1 gene mutations in sporadic carcinoid tumors of the lung. Human Molecular Genetics 6 2285-2290. (doi:10.1093/hmg/6.13.2285)
4. Garcia-Yuste M, Matilla JM, Cueto A, Paniagua JM, Ramos G, Canizares MA & Muguruza I 2007 Typical and atypical carcinoid tumours: analysis of the experience of the Spanish Multi-centric Study of Neuroendocrine Tumours of the Lung. European Journal of Cardio-Thoracic Surgery 31 192-197. (doi:10.1016/j.ejcts.2006.11.031)
5. Hassan MM, Phan A, Li D, Dagohoy CG, Leary C & Yao JC 2008 Risk factors associated with neuroendocrine tumors: A U.S.-based case-control study. International Journal of Cancer 123 867-873. (doi:10.1002/ijc.23529)
6. Hughes CM, Rozenblatt-Rosen O, Milne TA, Copeland TD, Levine SS, Lee JC, Hayes DN, Shanmugam KS, Bhattacharjee A, Biondi CA et al. 2004 Menin associates with a trithorax family histone methyltransferase complex and with the hoxc8 locus. Molecular Cell 13 587-597. (doi:10.1016/S1097-2765(04)00081-4)
7. Jakobovitz O, Nass D, DeMarco L, Barbosa AJ, Simoni FB, Rechavi G & Friedman E 1996 Carcinoid tumors frequently display genetic abnormalities involving chromosome 11. Journal of Clinical Endocrinology and Metabolism 81 3164-3167. (doi:10.1210/jc.81.9.3164)
8. Kaplan B, Stevens CW, Allen P, Liao Z & Komaki R 2003 Outcomes and patterns of failure in bronchial carcinoid tumors. International Journal of Radiation Oncology, Biology, Physics 55 125-131. (doi:10.1016/S0360-3016(02) 03796-3)
9. Karnik SK, Chen H, McLean GW, Heit JJ, Gu X, Zhang AY, Fontaine M, Yen MH & Kim SK 2007 Menin controls growth of pancreatic beta-cells in pregnant mice and promotes gestational diabetes mellitus. Science 318 806-809. (doi:10.1126/science.1146812)
10. Moreno A, Akcakanat A, Munsell MF, Soni A, Yao JC & Meric-Bernstam F 2008 Antitumor activity of rapamycin and octreotide as single agents or in combination in neuroendocrine tumors. Endocrine-Related Cancer 15 257-266. (doi:10.1677/ERC-07-0202)
11. Öberg K, Kulke M, Pavel M, Phan A, Hoosen S, St. Peter J, Cherfi A & Yao JC 2010 Prognostic and predictive value of chromogranin A and neuron-specific enolase in patients (PTS) with advanced pancreatic neuroendocrine tumors (pNET) treated with everolimus. Annals of Oncology 21 (Supplement 8) viii266 853P. (doi:10.1093/annonc/mdq524)
12. Ruan W, Fahlbusch F, Clemmons DR, Monaco ME, Walden PD, Silva AP, Schmid HA & Kleinberg DL 2006 SOM230 inhibits insulin-like growth factor-I action in mammary gland development by pituitary independent mechanism: mediated through somatostatin subtype receptor 3? Molecular Endocrinology 20 426-436. (doi:10.1210/me.2005-0283)
13. Scacheri PC, Davis S, Odom DT, Crawford GE, Perkins S, Halawi MJ, Agarwal SK, Marx SJ, Spiegel AM, Meltzer PS et al. 2006 Genome-wide analysis of menin binding provides insights into MEN1 tumorigenesis. PLoS Genetics 2 e51. (doi:10.1371/journal.pgen.0020051)
14. Tai P, Tonita J, Yu E & Skarsgard D 2003 Twenty-year follow-up study of long-term survival of limited-stage small-cell lung cancer and overview of prognostic and treatment factors. International Journal of Radiation Oncology, Biology, Physics 56 626-633. (doi:10.1016/S0360-3016(03)00070-1)
15. Travis WD, Rush W, Flieder DB, Falk R, Fleming MV, Gal AA & Koss MN 1998 Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid. American Journal of Surgical Pathology 22 934-944. (doi:10.1097/00000478- 199808000-00003)
16. Walch AK, Zitzelsberger HF, Aubele MM, Mattis AE, Bauchinger M, Candidus S, Prauer HW, Werner M & Hofler H 1998 Typical and atypical carcinoid tumors of the lung are characterized by 11q deletions as detected by comparative genomic hybridization. American Journal of Pathology 153 1089-1098. (doi:10.1016/S0002-9440(10)65653-2)
17. von Wichert G, Jehle PM, Hoeflich A, Koschnick S, Dralle H, Wolf E, Wiedenmann B, Boehm BO, Adler G & Seufferlein T 2000 Insulin-like growth factor-I is an autocrine regulator of chromogranin A secretion and growth in human neuroendocrine tumor cells. Cancer Research 60 4573-4581. (Pubitemid 32103642)
18. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A et al. 2008a One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35 825 cases in the United States. Journal of Clinical Oncology 26 3063-3072. (doi:10.1200/JCO.2007.15.4377)
19. Yao JC, Phan AT, Chang DZ, Wolff RA, Hess K, Gupta S, Jacobs C, Mares JE, Landgraf AN, Rashid A et al. 2008b Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. Journal of Clinical Oncology 26 4311-4318. (doi:10.1200/JCO.2008.16.7858)
20. Yao JC, Lombard-Bohas C, Baudin E, Kvols LK, Rougier P, Ruszniewski P, Hoosen S, St Peter J, Haas T, Lebwohl D et al. 2010 Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. Journal of Clinical Oncology 28 69-76. (doi:10.1200/JCO.2009.24.2669)
21. Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, Hobday TJ, Okusaka T, Capdevila J, de Vries EG et al. 2011 Everolimus for advanced pancreatic neuroendocrine tumors. New England Journal of Medicine 364 514-523. (doi:10.1056/NEJMoa1009290)
22. Zatelli MC, Piccin D, Vignali C, Tagliati F, Ambrosio MR, Bondanelli M, Cimino V, Bianchi A, Schmid HA, Scanarini M et al. 2007 Pasireotide, a multiple somatostatin receptor subtypes ligand, reduces cell viability in non-functioning pituitary adenomas by inhibiting vascular endothelial growth factor secretion. Endocrine-Related Cancer 14 91-102. (doi:10.1677/ERC-06-0026)
23. Zatelli MC, Minoia M, Martini C, Tagliati F, Ambrosio MR, Schiavon M, Buratto M, Calabrese F, Gentilin E, Cavallesco G et al. 2010 Everolimus as a new potential antiproliferative agent in aggressive human bronchial carcinoids. Endocrine-Related Cancer 17 719-729. (doi:10.1677/ERC-10-0097)